Match the technology to the wastewater and discharge endpoint
For pharmaceutical wastewater in Greenville, choose MBR when variable batches, limited land, or a stringent low-solids reuse endpoint dominate; choose conventional activated sludge (CAS) when wastewater is stable, land is available, and capital cost controls the decision. Both processes use aerobic biology, but MBR separates solids through membranes while CAS relies on gravity settling. The defensible choice requires campaign-based influent data, written discharge or reuse requirements, pretreatment review, and a common 10-year lifecycle comparison—not an equipment selection based on flow alone.
Pharmaceutical preparation wastewater can contain formulation residues, cleaning chemicals, solvents, antibiotic compounds, salts, laboratory waste, and washing streams. Each stream should be characterized separately because averaging a production campaign can conceal toxicity spikes, short-duration organic loads, and cleaning-event discharges.
HydropureWater's 2026 guide identifies pharmaceutical wastewater stressors of 5–15 g/L NaCl salinity and COD swings of 1,500–8,000 mg/L. Those are illustrative design stressors, not universal Greenville loads. Use them to define sampling and testing questions, then replace them with measured site data.
Obtain the applicable discharge conditions directly from the Greenville receiving authority. If treated water will be reused, obtain a separate water-quality specification from the reuse recipient. The supplied evidence establishes no verified Greenville-specific pharmaceutical effluent limit, so a permit condition or reuse requirement should not be invented. The Greenville sewer-compliance guide can support the procurement framework, but regulatory confirmation remains necessary.
| Site condition | Initial technology direction | Evidence required before selection |
|---|---|---|
| Stable flow and load; land available; gravity separation proven | Evaluate CAS first | Production schedule, campaign data, clarifier performance, 10-year lifecycle cost |
| Batch-variable wastewater; constrained footprint; low-solids endpoint | Evaluate MBR first | Load envelope, pretreatment trial, membrane duty cycle, cleaning plan, availability |
| Existing aeration tank with separation retrofit possible | Evaluate hybrid separately | Structural, hydraulic, piping, controls, and civil assessment plus retrofit guarantee |
| Concentrated solvent, antibiotic, or cleaning discharge | Do not send directly to the main bioreactor | Stream-specific analysis, segregation strategy, mass balance, and pretreatment design |
| Water reuse with chemical or process-quality requirements | Assess MBR plus endpoint-specific polishing | Written reuse specification and validation of the complete treatment train |
The initial data request should cover at least 30 days or one campaign representative of actual production. It should link each sample to production conditions, cleaning events, and batch discharges, and record COD, TOC or BOD, pH, salinity, toxicity indicators, relevant solvents, flow, and temperature. A composite sample alone will not support a defensible design.
Compare biological performance and solids separation
CAS and MBR use aerobic microorganisms to degrade biodegradable organics, but their solids-separation mechanisms create different hydraulic and operating risks. CAS uses a secondary clarifier and gravity settling; MBR retains solids on ultrafiltration or microfiltration membranes.
HydropureWater's 2026 commercial guide cites MBR mixed liquor suspended solids of 8,000–12,000 mg/L, compared with 2,000–4,000 mg/L for CAS. At the same food-to-microorganism ratio, it reports an MBR aeration-tank volume reduction of 40–50%. The higher retained biomass can improve solids separation, but it does not make either process tolerant of salt, solvents, antibiotics, or toxic cleaning chemicals.
The same 2026 guide cites MBR design targets of COD no greater than 50 mg/L, TSS no greater than 5 mg/L, and turbidity below 1 NTU. Its cited CAS ranges are COD of 80–150 mg/L and TSS of 15–30 mg/L. These are commercial comparison targets, not universal guarantees, regulatory limits, or acceptance criteria for a Greenville project.
Elsevier's academic study titled Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment supports compound-specific evaluation. Biological degradation, sorption to sludge, membrane retention, and subsequent solids handling can distribute pharmaceutical residues differently. Neither process should be credited with complete removal of every residual. The academic record supplied here identifies the research question but does not provide a verified Greenville performance guarantee.
| Parameter | Conventional activated sludge | Membrane bioreactor | Procurement interpretation |
|---|---|---|---|
| Biological separation | Aerobic biomass followed by secondary clarification | Aerobic biomass with membrane solids retention | Compare biological treatment separately from solids separation |
| MLSS cited by HydropureWater's 2026 guide | 2,000–4,000 mg/L | 8,000–12,000 mg/L | Require bidders to state the proposed design MLSS and loading basis |
| COD cited by the 2026 guide | 80–150 mg/L | ≤50 mg/L | Commercial targets only; tie guarantees to measured influent and written endpoint conditions |
| TSS cited by the 2026 guide | 15–30 mg/L | ≤5 mg/L | Specify sampling method, operating period, and remedy |
| Turbidity cited by the 2026 guide | Not provided in the supplied research | <1 NTU | Require a defined compliance test rather than a generic clarity claim |
| Principal operating concern | Clarifier carryover, floc disruption, and solids washout | Membrane fouling, transmembrane pressure, cleaning demand, and scouring | Compare failure modes and redundancy under the verified load envelope |
| Pharmaceutical residues | Require compound-specific evaluation | Require compound-specific evaluation | Do not infer complete removal from either process |
For a Greenville comparison, require each bidder to fill the same performance table with proposed MLSS, hydraulic retention time, aeration-tank volume, solids-loading rate, membrane area or module count, design flux, secondary-clarifier area, and compliance testing methods. Any integrated MBR membrane bioreactor system proposal should then be evaluated against those same endpoint and operating assumptions.
Price the footprint, maintenance, and operating risks

MBR's commercial advantage is compact solids separation, while its commercial disadvantage is the equipment and operating burden associated with membranes, scouring, cleaning, and redundancy. HydropureWater's 2026 guide cites a 50–60% overall footprint reduction and a 20–40% CAPEX premium over CAS. Its integrated MBR catalog separately describes a 60% smaller footprint than conventional systems. These are commercial comparison figures, not Greenville site valuations.
The 2026 guide also cites routine clean-in-place every 6–12 months using dilute sodium hypochlorite or citric acid. That interval is a maintenance planning assumption, not a guarantee. Actual chemistry, membrane flux, operating temperature, and pharmaceutical wastewater constituents must validate cleaning frequency, chemical dose, and expected membrane life.
The DF Series uses 0.1 μm PVDF flat sheets with integrated aeration for scouring. Its supplied configurations span 80–225 m² and produce 32–135 m³/day; the integrated MBR catalog spans 10–2,000 m³/day. These catalog bounds identify candidate configurations only. Flow alone cannot select a unit because batch peaks, organic loading, MLSS, membrane flux, pretreatment, redundancy, and the endpoint must also be included in sizing.
| 10-year cost or risk item | CAS bid requirement | MBR bid requirement | Hybrid bid requirement |
|---|---|---|---|
| Installed capital | Reactor, clarifier, aeration, piping, controls, electrical, civil work, and site utilities | Same boundary plus membranes, scour blowers, cleaning skid, controls, and redundancy | Define retained tank, replacement separation equipment, modifications, and temporary treatment |
| Membrane replacement | Not applicable | Replacement schedule or condition criteria, unit cost, freight, installation, and downtime | Apply only to the proposed membrane section |
| Clean-in-place | Not applicable | Chemical type, dose, consumption, labor, frequency, membrane life, and lost production | Price the MBR-specific cleaning scope |
| Blowers and electricity | Aeration and miscellaneous plant loads | Biological aeration plus scour blowers and membrane-system loads at the duty cycle | Separate retained aeration from membrane scouring |
| Sludge handling | Measured mass and volume balance, dewatering, polymer, filtrate, and disposal | Same basis, including consequences of higher retained solids | Same basis, with incremental membrane-retention effects identified |
| Operator labor | Process control, clarifier operation, sampling, and maintenance | Add membrane monitoring, cleaning, condition assessment, and membrane replacement | Quantify additional membrane-related labor |
| Redundancy | Clarifier and critical equipment standby strategy | Trained membrane modules, blowers, controls, and operating capacity during cleaning or failure | State which capacity remains available during maintenance |
| Avoided treatment | Credit only steps proven unnecessary for the selected endpoint | Credit avoided tertiary treatment only when the reuse or discharge specification permits | Credit only verified avoided steps |
HydropureWater's 2026 guide cites a general land range of USD 800–2,000 per m² and states that the MBR premium may be recovered in 3–5 years where footprint is binding. Neither figure is a Greenville valuation. Substitute the site's actual land or brownfield-space value and calculate savings only from documented reclaimed area, avoided tertiary treatment, or other verified operating differences. The MBR cost-per-m3 guide provides a commercial starting point, while the DF Series membrane module describes the candidate configuration and operating basis.
Build the pretreatment and reuse treatment train
Equalization is a core treatment requirement where batch production creates sharp loads, and pH adjustment may be necessary before biology. Concentrated pharmaceutical streams should be segregated rather than discharged directly into the main bioreactor.
HydropureWater's 2026 guide again cites 5–15 g/L NaCl salinity and COD swings of 1,500–8,000 mg/L as illustrative pharmaceutical stressors. These values frame testing and pretreatment screening; they do not establish the Greenville design load. Confirm whether those conditions occur, how long they last, and whether they inhibit biomass or impair membrane performance.
Where the endpoint requires additional solids removal, evaluate an ultrafiltration polishing system for pretreatment or final polishing. The catalog describes 0.03 μm PVDF systems with automatic backwash and air scour that accept up to 300 ppm turbidity. This catalog condition is not proof that the UF unit can accept the untreated pharmaceutical effluent; the selected feed must meet the stated condition or receive clarification.
Do not assume MBR effluent alone meets a reuse application's chemistry requirements. Obtain a written endpoint specification covering quality parameters, application conditions, monitoring frequency, and who accepts responsibility for deviation. If a reuse recipient requires additional treatment, price that unit and its operating burden in every bid.
| Treatment-train decision | Required evidence | Bid consequence |
|---|---|---|
| Equalization and pH control | Batch discharge records, flow, pH, COD, toxicity, and proposed mixing response | Include tank volume, mixing, chemical demand, and controls |
| Solvent or antibiotic stream segregation | Stream inventory, concentration, compatibility, and toxicity testing | Price dedicated collection and pretreatment or exclude unsupported direct discharge |
| UF before or after MBR | Turbidity at the UF inlet, required endpoint, and membrane compatibility | Identify the polishing duty and reject guarantees based only on nominal pore size |
| Sludge dewatering | Measured solids mass, volume, batch frequency, polymer demand, and filtrate quality | Compare a plate-and-frame filter press against alternatives on the same solids basis |
| Disposal | Permit, destination, transport assumptions, and cake acceptance criteria | Credit avoided hauling only when supported by the mass balance |
Sludge mass, dewatering demand, filtrate quality, and disposal route belong in the same comparison. A high-performing liquid effluent does not establish a favorable solids balance. Conversely, MBR's membrane retention does not establish that the resulting sludge can be dewatered or disposed of at an acceptable cost.
Issue a comparable Greenville procurement brief

A comparable bid must price CAS, MBR, and any hybrid against one verified flow, influent envelope, effluent target, footprint boundary, operating assumption set, and 10-year lifecycle basis. Otherwise, differences in treatment scope will make the bids non-comparable.
The site-data package should include production schedules, cleaning and batch-discharge records, COD, TOC or BOD, pH, salinity, toxicity indicators, solvent data, flow, temperature, existing aeration-tank information, and the confirmed discharge or reuse specification. If those records do not cover a representative campaign, state the limitation rather than substituting an average design flow.
Performance guarantees should identify the tested parameter, test method, influent envelope, operating condition, averaging period, and remedy. Relevant guarantees include flow, solids loading, MLSS, turbidity, COD, membrane flux, cleaning frequency, availability, and redundancy. A generic statement that the effluent is suitable for reuse is not an acceptance criterion.
| Fillable procurement field | Buyer input | Bidder response |
|---|---|---|
| Verified flow and contaminant envelope | Campaign data, production schedule, cleaning events, analytical results | Design flow, peak load, loading basis, and compliance range |
| Discharge or reuse endpoint | Written authority conditions or recipient specification | Treatment train, test methods, and point-of-compliance definition |
| Footprint and utilities | Available area, elevation, electrical capacity, access, and site constraints | Equipment dimensions, civil work, utility loads, and installed boundary |
| 10-year cash flow | Local energy, chemical, labor, disposal, land, and replacement assumptions | Annual and lifecycle costs for CAS, MBR, and hybrid |
| Performance guarantees | Required parameters, methods, periods, and remedies | Measured values, exclusions, and contractual commitments |
| Availability and redundancy | Operating schedule, maintenance access, critical spares | Installed capacity during each outage scenario |
| Pilot or side-stream evidence | Uncertainty in toxicity, salinity, solvents, or batch effects | Protocol, results, acceptance criteria, and design consequences |
| Supplier support | Operator capability and local-service expectations | Training, spare parts, response time, controls support, and replacement lead time |
Make pilot or side-stream testing a prerequisite before award when toxicity, salinity, solvent, or batch effects remain uncertain. The pilot should test the proposed biology, membrane behavior, cleaning response, and achievable endpoint across representative conditions. A successful pilot without a defined transfer to full scale is not enough; require the design basis, scale-up method, and acceptance criteria.
Before final award, verify spare membranes or replacement elements, clean-in-place chemicals, scour blowers, controls, critical accessories, operator training, and local technical support. The supplied evidence supports an evaluation framework; it does not establish that either technology automatically satisfies a Greenville permit.
Frequently Asked Questions
When can the commercial MBR premium be justified?
HydropureWater's 2026 guide cites a 20–40% CAPEX premium over CAS and a possible 3–5-year premium-recovery period where footprint is binding. For this Greenville decision, require the bidder to show which verified site costs the premium avoids: land, tertiary treatment, labor, or another documented item. Do not treat the general USD 800–2,000 per m² land range as a local valuation or claim a recovery period before inserting Greenville-specific inputs.
Why can flow alone not size an MBR or CAS system?
The required unit depends on verified flow, contaminant loading, batch variability, pretreatment, MLSS, solids-loading rate, membrane flux, and the discharge or reuse endpoint. The supplied DF Series configurations span 32–135 m³/day, while the integrated MBR catalog spans 10–2,000 m³/day. Ask each bidder to state its proposed duty point and all design assumptions; a catalog capacity match alone is not a valid size selection.
Which supplier evidence should be checked before selecting MBR?
Request guarantees tied to the measured pharmaceutical influent envelope, including membrane flux, cleaning frequency, chemical consumption, equipment availability, redundancy, spare-parts commitments, operator training, and local service. The cited 6–12-month clean-in-place interval should be treated as a hypothesis to validate, not as a substitute for site chemistry or contractual operating criteria.
Why should no Greenville effluent limit be inserted into the bid?
The supplied evidence contains no verified Greenville-specific limit for this pharmaceutical application. Obtain written conditions from the applicable receiving authority and a separate specification from any reuse recipient. Until confirmed, use the MBR and CAS values as labeled commercial comparison targets, then replace them with the confirmed permit or reuse criteria before bidders price performance guarantees.